Literature DB >> 11918987

Dopaminergic dysfunction in alcoholism and schizophrenia--psychopathological and behavioral correlates.

A Heinz1.   

Abstract

Dysfunction of central dopaminergic neurotransmission has been implicated in the pathogenesis of schizophrenia as well as drug and alcohol dependence. Different drugs of abuse stimulate dopamine release in the ventral striatum and thus reinforce drug consumption. Increased subcortical dopamine release has also been associated with the pathogenesis of positive symptoms in schizophrenia and may be driven by a prefrontal dopaminergic dysfunction. These seemingly heterogeneous findings may be explained by recent research in non-human primates. According to these studies, reward anticipation but not anticipated reward consumption is accompanied by a phasic dopamine release in the striatum and prefrontal cortex. In the striatum, phasic dopamine release primarily affects motivation, psychomotor activation and reward craving, while in the prefrontal cortex, dopaminergic stimulation is involved in the activation of working memory and reward anticipation. In alcoholism, previously neutral stimuli that have been associated with alcohol intake can become conditioned cues which activate phasic dopamine release and reward craving. In schizophrenia, stress-induced or chaotic activation of dopamine release may attribute incentive salience to otherwise irrelevant stimuli and thus be involved in the pathogenesis of delusional mood and other positive symptoms. Studies in humans and non-human primates emphasize the role of dopaminergic neurotransmission in reward anticipation and its dysfunction in different neuropsychiatric diseases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11918987     DOI: 10.1016/s0924-9338(02)00628-4

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  77 in total

Review 1.  Dopaminergic dysfunction in schizophrenia: salience attribution revisited.

Authors:  Andreas Heinz; Florian Schlagenhauf
Journal:  Schizophr Bull       Date:  2010-05-07       Impact factor: 9.306

Review 2.  [Genetic and pharmacological effects on prefrontal cortical function in schizophrenia].

Authors:  Andreas Heinz; Dieter F Braus; Berenice Romero; Jürgen Gallinat; Imke Puls; Georg Juckel; Daniel R Weinberger
Journal:  Nervenarzt       Date:  2004-09       Impact factor: 1.214

3.  Effective and Neurobiologically Sound.

Authors:  Andreas Heinz; Tomislav Majić
Journal:  Dtsch Arztebl Int       Date:  2015-10-09       Impact factor: 5.594

4.  Pre-ejection period reactivity to reward is associated with anhedonic symptoms of depression among adolescents.

Authors:  Joshua J Ahles; Amy H Mezulis; Sheila E Crowell
Journal:  Dev Psychobiol       Date:  2017-04-13       Impact factor: 3.038

5.  Reward system activation in schizophrenic patients switched from typical neuroleptics to olanzapine.

Authors:  Florian Schlagenhauf; Georg Juckel; Michael Koslowski; Thorsten Kahnt; Brian Knutson; Theresa Dembler; Thorsten Kienast; Jürgen Gallinat; Jana Wrase; Andreas Heinz
Journal:  Psychopharmacology (Berl)       Date:  2007-12-21       Impact factor: 4.530

Review 6.  [Frontal brain volume reduction due to antipsychotic drugs?].

Authors:  V Aderhold; S Weinmann; C Hägele; A Heinz
Journal:  Nervenarzt       Date:  2015-03       Impact factor: 1.214

7.  Regional patterns and clinical correlates of basal ganglia morphology in non-medicated schizophrenia.

Authors:  Martina Ballmaier; Florian Schlagenhauf; Arthur W Toga; Jürgen Gallinat; Michael Koslowski; Michele Zoli; Cornelius Hojatkashani; Katherine L Narr; Andreas Heinz
Journal:  Schizophr Res       Date:  2008-09-24       Impact factor: 4.939

8.  Altered representation of expected value in the orbitofrontal cortex in mania.

Authors:  Felix Bermpohl; Thorsten Kahnt; Umut Dalanay; Claudia Hägele; Bastian Sajonz; Tristan Wegner; Meline Stoy; Mazda Adli; Stephanie Krüger; Jana Wrase; Andreas Ströhle; Michael Bauer; Andreas Heinz
Journal:  Hum Brain Mapp       Date:  2010-07       Impact factor: 5.038

9.  Psychotic Experiences in Schizophrenia and Sensitivity to Sensory Evidence.

Authors:  Veith Weilnhammer; Lukas Röd; Anna-Lena Eckert; Heiner Stuke; Andreas Heinz; Philipp Sterzer
Journal:  Schizophr Bull       Date:  2020-07-08       Impact factor: 9.306

Review 10.  Animal models for medications development targeting alcohol abuse using selectively bred rat lines: neurobiological and pharmacological validity.

Authors:  Richard L Bell; Helen J K Sable; Giancarlo Colombo; Petri Hyytia; Zachary A Rodd; Lawrence Lumeng
Journal:  Pharmacol Biochem Behav       Date:  2012-07-25       Impact factor: 3.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.